Antibiotic bacterial resistance is a serious medical problem with a high morbidity and mortality of the infected patients. Previously, Scandion Oncology announced that one of its compounds, SOM-001 and a number of analogues have strong anti-bacterial effects also in otherwise antibiotic resistant bacteria. Moreover, SOM-001 kills bacteria via a novel mechanism of action and further, resistance to SOM-001 has not been observed during in vitro conditions.
When testing SOM-001 in clinical samples obtained from patients with antibiotic resistant bacterial infections, SOM-001 demonstrated significant bacterial killing.
Scandion Oncology has now received the report on the in vivo effect of SOM-001. In these experiments, animals were infected with multi-resistant bacteria (MRSA) and treated with either SOM-001, Vancomycin or just vehicle. Scandion Oncology is pleased to announce that the results are positive demonstrating that SOM-001 is as effective as the positive control, the antibiotic drug Vancomycin, in killing MRSA bacteria. However, issues with certain controls were noted in the data from the experiments. This could suggest a potential interference with the vehicle used to solubilize SOM-001.
Based on the results obtained so far with SOM-001 in antibiotic resistant bacteria, Scandion Oncology has decided to proceed with the preclinical testing of SOM-001 and its analogues.
CEO Nils Brünner comments
“We are very encourage by the opportunity to target antibiotic resistance, which is a world-wide medical problem. We will now proceed with additional efficacy animal studies”.
For further information regarding Scandion Oncology, please contact:
Nils Brünner, CEO
Phone: +45 26 14 47 08
This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on May 15, 2020.
Scandion Oncology A/S is a biotechnology company that addresses and tackles one of the greatest challenges in modern oncology – the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company's leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. In addition to SCO-101 the Company has two other drug candidates, SCO-201 and SCO-301. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018.